1Ikeda D,Ikcda M,Dohara T,et al.Interleukin-6 stimulates growth of vas-cular smooth muscle cells in a PDGF-dependent manner[J].Am J Physi-ol,1991;260(5-2):H1713-7.
2Andus T,Geiger T,Kishimoto T,et al.Action of recombinant human in-terleukin-6,interleukin-1 beta and tumor necrosis factor alpha on the mR-NA induction of acute-phase proteins[J].Eur J Immunol,1988;18(5):739-46.
4Sun WH,Binkley N,Ershoer WB.A trial of recombinant interleukin-6 inrhesus monkeys[J].(Abstract)Gerontologist,1992;32(1):156.
5Eickelberg O,Roth M,Block LH.Effect of amlodipine on gene expres-sion and estracellular matrix formation in human vascular smooth musclecells and fibroblasts:implication for vascular protection[J].Int J Cardiol,1997;62(2):31-7.
2Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of Creactive protein on human endothelial cells [ J ]. Circulation, 2000, 102(18) :2165 -2168.
3Ross R. Atherosclerosis-an inflammatory disease[J]. N Engl J Med, 1999,340(2) : 115 - 126.
4Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenie effects of C-reactive protein[ J]. Circulation ,2002,105(16) : 1890 - 1896.
5Schieffer B,Schieffer E,Hilfiker-Kleiner D. Expression of Angiotensin Ⅱ and Interleukin 6 in Human Coronary Atherosclerotie Plaques : Potential Implications for Inflammation and Plaque Instability [ J ]. Circulation ,2000,101 : 1372 - 1378.
6Wassmann S, Stumpf M, Strehlow K, et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin Ⅱ type Ⅰ receptor[J]. Cire Res,2004,94(4) :534 -541.
7Han Y, Runge MS, Brasier AR. Angiotensin II induces intedeukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors [ J ]. Circ Res, 1999,84(6) :695 -703.
8Park SY,Lee JH,Kim YK,et al. Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein- 1 expression via lectin - like receptor for oxidized low-density lipoprotein receptor activation [ J ]. J Pharmacol Exp Ther, 2005,312 ( 3 ) : 1241 - 1248.
9Lee JH, Oh GT, Park SY, et al. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-│alpha│ Formation in low-dDensity lLipoprotein teceptor-null mice fed high cholesterol [ J ]. J Pharmacol Exp Ther,2005,313 ( 2 ) :502 - 509.
2Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension [J].N Engl J Med, 2014, 370 (15): 1393 -1401.
3Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low- income countries [ J]. JAMA, 2013, 310 (9): 959-968.
4Kodama S, Inoue Y, Miyoshi K, et al. Additive antihypertensive and anti - hypertrophic effects of long acting Ca blockers in uncontrolled hypertensive patients with angiotensin receptor blocker based treatment [J]. Int Heart J, 2009, 8 (5): 555-570.
5Sung KC, Lim S, Rosenson RS. Hyperinsulinemia and homeostasis model assessment of insulin resistance as predictors of hypertension : a 5 - year follow - up study of Korean sample [J]. Am J Hypertens, 2011, 24 (9): 1041-1045.
7Ogihara T, Asano T, Ando K, et al. Insulin resistance with enhanced insulin signaling in high salt diet fed rats [J]. Diabetes, 2001, 50 (3): 573-583.
8Ueshiba H, Miyachi Y. Effects of the long - acting calcium channel blockers, amlodipine, mani - dipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients [ J ]. Intem Med, 2004, 43 (7): 561-565.
